One out of every six men in this country is struggling with prostate cancer at this very moment. This not only affects the men but the women and their families who love them.

Based on the latest scientific research, many different nutrients have shown promise in the prevention and control of prostate cancer.

Combining these nutrients in effective amounts allows the cancer to be attacked from all sides at once-while undergoing conventional forms of treatment-both inhibiting the cancer and promoting long- lasting health.

They can be used at all stages and in conjunction with all conventional treatment protocols.

There are many supplements that can be used but I would like to discuss the cutting edge research on one of the most important: modified citrus pectin.

Modified Citrus Pectin

Modified citrus pectin (MCP), a compound derived from the pith of citrus fruit peels, is absolutely essential in the prevention and treatment of prostate cancer.

It directly attacks cancer, thereby reducing the disease-but at the same time it has properties that enhance the overall health of the individual, making it a true super nutrient.

I would like to discuss how it can do all this.

Cancer cells are different from normal cells in a number of important ways.

First and foremost, they have lost control of the "cell cycle"-a natural cycle that controls when cells live, when they divide, and when they die.

Cancer, by definition, grows out of control without any of the normal checks and balances.

As such, many cancer killing herbs, nutrients, and drugs function by getting cancer cells to enter back into the cell cycle and die a normal death.

Another important difference that cancer cells have is they "look" different from normal cells.

All cells have different molecules on their surface, and these molecules allow the cells to communicate with each other and their environment.

These molecules have multiple functions:

They are receptors for neurotransmitters or hormones.

They are markers that identify what type of cell it is.

They are "hands" that let the cell stick in place or move around.

Cancer cells can have several distinct qualities that separate them from healthy cells.

The may have more of one type or less of another-or, they have markers on their surface that clearly state "Hey-I'm an out-of-control cancer cell!"

These changes on the surface of cancer cells allow white blood cells to recognize them as cancerous and kill them.

One type of molecule that cancer cells have too many of is called galectin-3.

Galectin-3 molecules function as "hands" and help the cancer spread in many ways.

First, they are important in reaching out and stimulating the growth of new blood vessels-a process called angiogenesis.

This allows the cancer to get the blood-flow and nutrients it needs to grow out of control.

Second, galectins allow cells that break off from the primary tumor to aggregate or clump together in the bloodstream-this allows the cancer cells to move to a new site in the body.

Finally, the galectin "hand" can grab hold of the new location and complete the spread of the cancer-a process called metastasis.

Modified citrus pectin (MCP) is a natural substance that can bind to galectin molecules and block them-which means the cancer cells can't spread and grow.

Early research on prostate cancer showed that oral administration of MCP to rodents resulted in a dramatic reduction in prostate cancer metastasis to the lungs.

More recent research from this same group of scientists has extended the protection of MCP to breast and colon cancer and has shown that MCP blocks the growth of primary tumors and the formation of new blood vessels.

A commercially available form of modified citrus pectin-Pecta-Sol C- was developed in response to the positive results of the animal studies and was tested in men with prostate cancer.

A pilot trial using PectaSol MCP at 15 grams a day and a subsequent phase II trial both showed that MCP slows the progression of prostate cancer as evidenced by a reduction in the rate of PSA rise.

The phase II trial involved men where primary conventional treatment was initially successful, but subsequently their PSA began to climb again, representing cancer recurrence.

This time, 70 percent of the trial participants showed a significant reduction in the rise of their PSA climb.

Recent advances have introduced a new, more potent form of this compound (PectaSol-C)- which has since demonstrated even more compelling results among a group of late-stage cancer patients.

In late 2007, researchers at Albert-Ludwigs University in Freiburg, Germany enrolled 49 patients, each with advanced state solid tumors of varying types-colon cancer, prostate cancer, breast cancer, kidney cancer, lung cancer, cervical cancer, liver cancer, and pancreatic cancer, among others.

Each patient had completed conventional treatments, including surgery, chemotherapy, and radiation without success-nearly 90 percent of the cancers had metastasized.

During the trial, patients were administered 5 grams of MCP orally, three times a day.

They would later be evaluated for clinical benefit-including pain reduction, improved physical functioning, increased appetite and sleep, and reduced fatigue.

At just eight weeks, the results were already overwhelmingly positive, with 20.7 percent of the patients showing an overall clinical benefit response and stabilization of disease.

By the conclusion of the study, response rates continued to improve, with a majority of the patients showing improved quality of life and pain reduction.

And perhaps most remarkably, one patient with metastasized prostate cancer demonstrated a 50 percent decrease in PSA levels at 16 weeks, accompanied by a significant increase in clinical benefit.

More recent research-published in the journal Integrative Cancer Therapies, and performed in conjunction with Columbia University-points to the potential mechanism of this action.

Laboratory results indicate that MCP can inhibit cell proliferation and apoptosis in prostate cancer cell lines (including androgen-dependent and androgen-independent cells), induce apoptosis by the cleavage of Caspase-3, and inhibit cell proliferation by reducing MAP kinase signaling.

This ability to induce apoptosis in androgen-independent prostate cancer cell lines is especially significant, as it is the more aggressive form of cancer that can metastasize and lead to death.

Any help in slowing down the progression of this cancer has a direct effect on prolonging a patient's life.

Another unique quality attributed to MCP is its effectiveness as a chelating agent.

Heavy metals, in conjunction with the abundant presence of environmental toxins and xenoestrogens, constitute a dangerous insult to the body through DNA damage, hormonal modulation, immune suppression, oxidative stress, and hyper-inflammation.

And they are of particular concern in prostate cancer.

The chelation properties of MCP have been confirmed in several clinical trials-showing that in healthy individuals, MCP can safely and gently increase the urinary excretion of toxic metals such as mercury, cadmium, arsenic and lead.

These results have been paired with significant improvement in various clinical symptoms, suggesting that MCP's ability to remove heavy metals and environmental toxins on an ongoing basis may be of great benefit to cancer patients.

It must be noted that PectaSol-C is the only form of MCP that has been validated in human clinical trials.

This is important, since not all MCPs are the same-and no other product on the market matches the chemical specifications of PectaSol-C.

If the molecular weight of the MCP is too high it can't be absorbed into the bloodstream-if it is too low it won't effectively block all the galectin sites.

Another property, the degree of esterification, must be below 5% in order to get optimal binding.

If you want the effects seen in any of these clinical studies, you must use the same preparation, in appropriate doses according to your needs.

I highly recommend the following book:

Dr. Katz's Guide to Prostate Health: From Conventional to Holistic Therapies [Paperback]

Aaron E. Katz (Author)

Paperback: 248 pages

Publisher: Freedom Publishing Company (IL); 1 edition (September 2005)

Language: English

ISBN-10: 1893910377

ISBN-13: 978-1893910379

Aaron E. Katz, MD is director of the Center for Holistic Urology at Columbia University Medical Center and Associate Professor of Clinical Urology at Columbia University College of Physicians and Surgeons.

Since the publication of this book, Dr. Katz has done a great deal of additional research in prostate health. He has recently published two clinical trials showing the effectiveness of PectaSol-C Modified Citrus Pectin in the treatment of Prostate Cancer.

Modified Pectin Research for Prostate Cancer Prevention and Treatment Three recently published clinical medical trials are listed below for reference: This published research is all available on Public Medline at www.ncbi.nlm.nih.gov/pubmed Just enter the name of the trial to obtain more information. Author: Yan, J., & Katz, A. E. Trial Name: PectaSol-C Modified Citrus Pectin Induces Apoptosis and Inhibition of Proliferation in Human and Mouse Androgen-Dependent and - Independent Prostate Cancer Cells Medical Journal: Integrated Cancer Therapy 2010 9: 197-203. Author: Yan, J., & Katz, A. E. Trial Name: ProstaCaid Induces G2/M Cell Cycle Arrest and Apoptosis in Human and Mouse Androgen-Dependent and - Independent Prostate Cancer Cells Medical Journal: Integr Cancer Ther 2010 9: 186-196. Author: Wojnowski, R., Jaing, J., Jedinak, A., and Sliva, D. Trial Name: Modified citrus pectin enhances the effect of novel dietary supplement formulas inhibition of invasiveness of breast and prostate cancer cells by down-regulation of urokinase plasminogen activator (uPA) secretion Medical Journal:Experimental Biology 2010, Anaheim, CA, April, 2010. (FASEB J. 24: 207.4) Learn More About Age Management Medicine

Prostate Cancer Prevention and Treatment One out of every six men in this country is struggling with prostate cancer at this very moment. Addressing this disease in a way that minimizes side effects and maximizes your health and longevity is possible. I have written an e-booklet that is posted in the Member Center of my website on Prostate Cancer Prevention and Treatment. It explains in detail the treatment options- some which you may never have even heard of. Research in prostate cancer prevention and treatment continues to increase and staying informed is the best weapon against this disease. Learn More About Age Management Medicine

Learning More about Prostate Cancer Prevention and Treatment I invite you to read the e-booklet that I have posted, read the book that Dr. Katz has written and do more of your own research on Pectasol-C Modified Citrus Pectin. Learn More About Age Management Medicine

Prostate Cancer Prevention in men is an important part of an Age Management Medicine program.

It is important to learn about the most cutting edge research in this area and how to apply it to your program for optimal health.

Wishing you the best in health,

Learn More About Age Management Medicine- Subscribe to the Member Center Today.

Dr. Casas offers COMPLIMENTARY access to the Member Center to her currently enrolled patients.